Lupin’s subsidiary receives USFDA approval for SUPRAX (Cefixime) Capsules, 400 mg

Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc (collectively, Lupin) has received an approval for SUPRAX (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (USFDA). The company is also expecting to commence shipping of the product in the near future. 

The approval will expand Lupin’s range of SUPRAX dosage forms available to treat the approved indications in appropriate patients. Currently, SUPRAX is available as 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.  

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.